Apellis’s Pegcetacoplan Hits 'Grand Slam' Scenario In Rare Kidney Disease

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

A Phase III trial testing pegcetacoplan in patients with two rare kidney diseases demonstrated impressive efficacy, outperforming what Novartis showed with Fabhalta in a similar trial.

• Source: Shutterstock

Apellis Pharmaceuticals, Inc. and its partner Swedish Orphan Biovitrum AB (Sobi) appear well positioned with their complement inhibitor pegcetacoplan to compete in a market for two rare kidney diseases that have no approved treatments – but could soon become competitive.

Key Takeaways

  • Apellis and Sobi’s pegcetacoplan demonstrated strong efficacy in the treatment of two rare kidney diseases, C3G and IC-MPGN, in a Phase III trial.

Apellis announced positive results from the Phase III VALIANT trial testing pegcetacoplan in patients with C3 glomerulopathy (C3G) or primary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Genitourinary

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Borealis Seeks Aurora In RNA-Based Drugs For Renal Disease

 
• By Alaric DeArment

With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.

Pathalys Raises $105m To Pave Path Toward US Commercialization

 
• By Mandy Jackson

The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.